---
schema_version: "secwatch.filing_event.v1"
accession: "0001174947-25-000129"
form_type: "8-K"
ticker: "CNMD"
cik: "0000816956"
company_name: "CONMED Corp"
filed_at: "2025-02-05T23:59:59+00:00"
generated_at: "2026-05-27T03:07:42.936215+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CONMED Q4 2024 sales $345.9M (+5.8% YoY), adjusted EPS $1.34; FY25 guidance issued

## Summary
- Q4 GAAP diluted EPS $1.08 (vs $1.05 YoY); adjusted diluted EPS $1.34 (+26.4%).
- Full-year 2024 sales $1,307.0M (+5.0% reported); adjusted EPS $4.17 vs $3.45 in 2023.
- Q4 single-use product sales +9.6% YoY; capital product sales declined 12.7%.
- FY2025 guidance: revenue $1.344-1.372B (4-6% constant currency growth); adjusted EPS $4.25-4.40.

## SEC filing metadata
- accession: 0001174947-25-000129
- form_type: 8-K
- ticker: CNMD
- cik: 0000816956
- company_name: CONMED Corp
- filed_at: 2025-02-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/816956/000117494725000129/0001174947-25-000129-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/816956/000117494725000129/form8k-33496_cnmd.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001174947-25-000129
- JSON: https://secwatch.observer/filing/0001174947-25-000129.json
- Plain text: https://secwatch.observer/filing/0001174947-25-000129.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.